Paul T Quinlan sold $30k of ORKA
General Counsel at Oruka Therapeutics, Inc.. 733 shares at an average of $41.30, traded Mar 16, 2026, filed Mar 17, 2026.
Score components
- +15RoleOfficer
- +5Trade size$30k at market
- 0Share of holdings soldSold 2.3% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +62.4%, 3m +63.9%, 6m +123.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000907654-26-000029, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | SOpen-market sale Common Stock | -733 | $41.30 | $30k | 31,767 | Mar 17, 2026 |
Related signals
Other insiders at Oruka Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $806k 9,999 shares | -41% | |
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $2.1M 25,000 shares | -3% | |
| 17Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $51k 533 shares | -4% | |
| 29Weak | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $936k 10,000 shares | -25% | |
| 29Weak | Oruka Therapeutics, Inc. | Arjun Agarwal Senior Vice President, Finance | $926k 10,019 shares | -40% | |
| 21Weak | Oruka Therapeutics, Inc. | Joana Goncalves Chief Medical Officer | $734k 7,947 shares | -20% | |
| 53Moderate | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $235k 2,452 shares | -0% | |
| 44Moderate | Oruka Therapeutics, Inc. | Laura Lee Sandler Chief Operating Officer | $87k 906 shares | -0% | |
| 40Moderate | Oruka Therapeutics, Inc. | Paul T Quinlan General Counsel | $99k 1,039 shares | -3% | |
| 30Weak | Oruka Therapeutics, Inc. | Lawrence Otto Klein Chief Executive Officer | $6.9M 75,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.